Dr Reddys Laboratories (RDY) FCF Margin (2024 - 2025)
Dr Reddys Laboratories (RDY) recorded quarterly FCF Margin of 25.15% in Q2 2025, up 19.63% quarter-over-quarter from 21.02% in Q3 2024, and up 742.0% on a YoY basis from 2.99% in Q2 2024.
Dr Reddys Laboratories (RDY) FCF Margin (2024 - 2025) Analysis & Trends
Dr Reddys Laboratories' FCF Margin history runs 2 years deep, the most recent figure standing at 25.15% for Q2 2025.
- In Q2 2025, FCF Margin rose 742.0% year-over-year to 25.15%; the TTM figure through Mar 2026 stood at 12.48% (up 301.0% YoY), while the FY2026 annual figure was 14.02%, up 203.0% from the prior year.
- FCF Margin was 25.15% for Q2 2025 at Dr Reddys Laboratories, up from 21.02% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 25.15% in Q2 2025 to a low of 17.73% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -429.96% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 13.24% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 32.62% |
| 10 | Dr Reddys Laboratories | 122.03 Mn | -51.98 Mn | 368.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 25.15% |
| Sep 30, 2024 | 21.02% |
| Jun 30, 2024 | 17.73% |